Compare Manulife Financial Corporation (MFC) vs Moderna, Inc. (MRNA) Price & Performance

Manulife Financial (MFC) trades at $42.56, down 1.91% today but remains near 52-week highs. The stock shows strong fundamentals with revenue growth from $46.2B in 2024 to $53.0B in 2025 and consistent profitability (12.07% net margin). Technical indicators are mixed with bullish moving averages but overbought RSI levels. Recent Q1 2026 earnings missed expectations despite strong Asia performance, while analyst consensus remains bullish with 57% buy ratings.

MFC presents a compelling value case with reasonable valuation (P/E 17.75) and dividend yield support. Key opportunities include AI integration partnerships and Asia growth, though risks include wealth management outflows and regulatory scrutiny. The stock's current technical overbought condition suggests potential near-term consolidation before resuming upward trajectory.

Moderna (MRNA) trades at $60.47, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported a net loss of -$2.82B in 2025, with revenue declining to $1.92B, though it has beaten EPS estimates in recent quarters. Recent news highlights progress in its cancer pipeline, including a Phase 1 study for mRNA-4200, and an EU contract for its RSV vaccine.

The outlook remains speculative with high execution risk as Moderna transitions beyond COVID-19 vaccines. While pipeline advancements offer long-term potential, persistent losses and negative margins pose significant challenges. Analyst consensus is cautious with a $49 price target, suggesting limited near-term upside amid ongoing fundamental headwinds.